# CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer

> **NCT06667050** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **West China Hospital** · enrollment: 58 (estimated)

## Conditions studied

- Gastric Adenocarcinoma

## Interventions

- **DRUG:** Chemotherapy plus sintilimab and bevacizumab

## Key facts

- **NCT ID:** NCT06667050
- **Lead sponsor:** West China Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-10-10
- **Primary completion:** 2026-10-31
- **Final completion:** 2027-10-31
- **Target enrollment:** 58 (ESTIMATED)
- **Last updated:** 2024-10-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06667050

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06667050, "CAPOX Plus Sintilimab and Bevacizumab Biosimilar (IBI305) for Neoadjuvant Treatment of Locally Advanced Gastric Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06667050. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*